Masafumi Toyoshima, MD, PhDFred Hutchinson Cancer Research Center Identification of Targeted Therapies for MYC-Amplified Ovarian Cancer By Functional Genomics The main goal of Dr. Toyoshima’s research is to investigate whether MYC synthetic lethal genes can be therapeutic targets for ovarian cancer in women whose MYC gene is amplified. Using a siRNA screening strategy this study […]
Read More
Melissa Thompson, PhDUniversity of Texas MD Anderson Cancer Center The Role of the Tumor Microenvironment in Ovarian Cancer Progression Ovarian cancer is the deadliest gynecological cancer, accounting for 15,520 deaths annually. Preliminary studies by Dr. Thompson indicate that the tumor microenvironment enables and promotes tumor progression and chemoresistance, possibly through the expression of SFRP2. With […]
Read More
Melissa Thrall, MDUniversity of Washington A population based evaluation of the use and outcomes of neoadjuvant chemotherapy The current standard of care for the treatment of advanced stage ovarian cancer involves surgery with a maximal effort to remove all visible tumor followed by the administration of platinum based chemotherapy. However not all women with advanced […]
Read More
Ramandeep Rattan, PhDMayo Clinic TCEAL7, a novel regulator of NFkB-IL-6/STAT3 pathway in ovarian cancer The causes of ovarian cancer are not well understood because of the complexity and the lack of understanding of the various genetic alterations in the development of ovarian cancer and its progression to chemoresistant disease. Dr. Rattan’s study is poised to […]
Read More
Andrew Wilson, PhDVanderbilt University Medical Center The Role of the Nuclear Orphan Receptor TR3/Nur77 in Ovarian Cancer Preliminary results have led to the hypothesis that TR3 is a marker of chemotherapy-induced apoptosis and a potential therapeutic target in ovarian cancer. In this study, three aims will be investigated by Dr. Wilson and his team. First, […]
Read More
Andre Lieber, MD, PhDFred Hutchinson Cancer Research Center Clonality Analysis in Ovarian Cancer In preliminary studies, Dr. Lieber’s laboratory has identified new markers for ovarian cancer ovca stem cells. In this new study, his team will continue to address the concept of ovarian cancer stem cells and the phenotypic plasticity of ovarian cancer cells. Dr. […]
Read More
Sandra Orsulic, PhDCedars-Sinai Medical Center Determinants of Drug Sensitivity in BRCA Deficient Cells: The Role of TUBB4 in Resistance to Paclitaxel Currently, post-operative chemotherapy for patients with sporadic and BRCA-associated ovarian cancers includes treatment with taxanes and platinum. However, there is an indication that patients with BRCA-associated cancers respond less favorably to taxanes. Dr. Orsulic […]
Read More
Identification of drugs that increase cisplatin uptake by inhibiting CTR2 CTR2 has shown to be a particularly attractive target against which to develop a drug that both inhibits tumor growth and sensitizes to platinum drugs. In this project, Dr. Howell will establish a robust assay to evaluate the function of CTR2 that can be used […]
Read More
Xiaolong He, PhDUniversity of Illinois The role of microRNA miR-124 in ovarian cancer Based on his previous work and recent results, Dr. Xiaolong He hypothesizes that microRNA miR-124 may function as a tumor suppressor. In this study, two specific aims are proposed to strengthen the hypothesis. Aim 1 is to examine the levels of miR-124 […]
Read More
William Foulkes, PhDMcGill University Health Center Novel target discovery in hereditary ovarian cancer by deep sequencing Ovarian cancer is an important cause of death and inherited susceptibility accounts for a substantial fraction of this cancer. Moreover, advances in knowledge of hereditary forms of cancer have led to insights into the more common, non-hereditary forms. Technological […]
Read More